RLYB - Rallybio Corp

8.22
-0.110   -1.338%

Share volume: 32,655
Last Updated: 04-17-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.19%

PREVIOUS CLOSE
CHG
CHG%
$8.33
-0.11
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 19%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.36%
1 Month
-9.57%
3 Months
1,236.59%
6 Months
1,389.40%
1 Year
3,000.72%
2 Year
367.05%
Key data
Stock price
$8.22
P/E Ratio 
N/A
DAY RANGE
$8.11 - $8.28
EPS 
-$1.12
52 WEEK RANGE
$0.24 - $11.49
52 WEEK CHANGE
$3,000.72
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
5.290 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
0.82
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$46,931
AVERAGE 30 VOLUME 
$75,047
Company detail
CEO: Martin W. MacKay
Region: US
Website: rallybio.com
Employees: 40
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Rallybio Corporation engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT)

Recent news